Vertiflex
Founded Year
2004Stage
Acquired | AcquiredTotal Raised
$181.78MValuation
$0000About Vertiflex
Vertiflex is a developer of minimally invasive interventions for spinal stenosis. Vertiflex is advancing Superion Indirect Decompression System, a minimally invasive spinal implant designed to treat moderate lumbar spinal stenosis. Once implanted, Superion is intended to reduce pressure on the affected nerves and allow patients to return to a more active lifestyle.
Vertiflex Headquarter Location
2714 Loker Ave. West Suite 100
Carlsbad, California, 92010,
United States
442-325-5900
Research containing Vertiflex
Get data-driven expert analysis from the CB Insights Intelligence Unit.
CB Insights Intelligence Analysts have mentioned Vertiflex in 1 CB Insights research brief, most recently on Aug 21, 2019.
Expert Collections containing Vertiflex
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Vertiflex is included in 2 Expert Collections, including Medical Devices.
Medical Devices
8,293 items
Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.
Health IT
7,900 items
Vertiflex Patents
Vertiflex has filed 45 patents.
The 3 most popular patent topics include:
- Bones of the vertebral column
- Orthopedic surgical procedures
- Neurosurgery
Application Date | Grant Date | Title | Related Topics | Status |
---|---|---|---|---|
11/8/2019 | 6/14/2022 | Bones of the vertebral column, Spinal cord disorders, Orthopedic surgical procedures, Musculoskeletal disorders, Neurosurgery | Grant |
Application Date | 11/8/2019 |
---|---|
Grant Date | 6/14/2022 |
Title | |
Related Topics | Bones of the vertebral column, Spinal cord disorders, Orthopedic surgical procedures, Musculoskeletal disorders, Neurosurgery |
Status | Grant |
Latest Vertiflex News
Jun 16, 2022
June 16, 2022 10:00 AM Eastern Daylight Time BOSTON--( BUSINESS WIRE )--New View Surgical, Inc., an emerging medical device company developing proprietary imaging and access technologies for minimally invasive surgery (MIS), announced today the appointment of Shane Johnson as Chief Commercial Officer. Shane will be responsible for leading the company's commercialization activities. Shane has more than 25 years of med tech commercial experience, having previously served as Vice President of Sales at Aerin Medical, Vertiflex, and Kyphon. “We are excited to welcome Shane to New View Surgical as we look forward to launching our novel VisionPort™ System into the US market later this year,” said Bryce Klontz, Chief Executive Officer of New View Surgical. “Shane’s leadership and broad experience in launching new and innovative devices will be essential to the success of our initial market release of the VisionPort System later this year.” Shane has a strong track record of success in the minimally invasive med tech industry, having built commercial capabilities, leading sales, operations, and marketing teams and cultivating strong key opinion leader relationships across multiple product lines and point of care environments. Of Shane’s 25 years of medical device experience, he has served the last 18 in commercial executive leadership roles. Shane joins us from Aerin Medical where he spent the last 5 years as the Vice President of Sales, creating the strategy and building the organization for the launch of two innovative products within the ENT space. Prior to Aerin Medical, Shane served as the VP of Sales at Vertiflex where he was the first commercial hire resulting in a $465M acquisition by Boston Scientific. Nearly half of his career was spent at Kyphon in progressive sales leadership roles, with his last role in the organization as a Vice President of Sales helping drive to a successful IPO and ultimately a $3.9B acquisition by Medtronic. “New View Surgical is taking the bold step to reimagine laparoscopic visualization and create exceptional clinical and economic value,” commented Shane. “I joined New View Surgical because of the unique opportunity to redefine how minimally invasive surgery can be accomplished. It is rare to find a product that can provide increased value across multiple stakeholders including the patient, physician and site of service. The vision that CEO, Bryce Klontz and the Board has created, along with the enormous market opportunity, positions New View Surgical to drive a paradigm shift within the minimally invasive surgical space.” The VisionPort™ System is a novel surgical imaging and access system that simplifies laparoscopic procedures by reducing the need for a separate camera port and camera holder and allows multiple simultaneous views of the operative field. In emerging markets, the VisionPort™ System will greatly reduce the capital-intensive equipment currently required to perform minimally invasive surgery, and thus, making state-of-the-art technology more accessible. The VisionPort System is intended to be used in a broad range of diagnostic and therapeutic procedures within the thoracic and abdominal cavities and is adaptable to a wide variety of surgical environments, representing a significant market opportunity. About New View Surgical, Inc. New View Surgical is an emerging medical device company focused on the development and commercialization of the VisionPort™ System, a novel surgical imaging and access system for minimally invasive surgery. The company is led by an experienced team of medical device innovators and commercial experts who have come together to design and commercialize impactful solutions that meet a variety of unmet market needs. The company’s proprietary VisionPort System combines multiple imaging and access devices into one simple, easy-to-use device that is disposable and is expected to bring a variety of clinical, operational, and financial advantages to minimally invasive surgery operating rooms around the world. For more information please visit www.newviewsurg.com or follow the company on Twitter at @NewViewSurg. Contacts
When was Vertiflex founded?
Vertiflex was founded in 2004.
Where is Vertiflex's headquarters?
Vertiflex's headquarters is located at 2714 Loker Ave. West, Carlsbad.
What is Vertiflex's latest funding round?
Vertiflex's latest funding round is Acquired.
How much did Vertiflex raise?
Vertiflex raised a total of $181.78M.
Who are the investors of Vertiflex?
Investors of Vertiflex include Boston Scientific, Alta Partners, New Enterprise Associates, Thomas McNerney & Partners, H.I.G. BioHealth Partners and 5 more.
Who are Vertiflex's competitors?
Competitors of Vertiflex include NICO, Spine Wave, Articulinx, Baxano, Minimus Spine and 14 more.
You May Also Like
Spartek Medical is developing a spine fusion implant, which are minimally invasive, for treatment of degenerative disc disease.
Kyphon develops and markets medical devices designed to restore spinal function using minimally invasive technologies. The company's KyphX(R) line of products is used in balloon kyphoplasty, a minimally invasive procedure to treat spinal fractures caused by osteoporosis or cancer. More information about the company can be found at www.kyphon.com.
Columna is focused on minimally invasive non-fusion spinal implants, a segment expected to represent 70% of the worldwide spine market.
Simpirica is developing a dynamic stabilization system designed to stabilize the spine in flexion and help patients return to more healthy, active lifestyles. The company's lead product, the LimiFlex Spinal Stabilization System, is typically used in conjunction with a surgical decompression for the treatment of lumbar spinal stenosis with or without degenerative spondylolisthesis.
Arbor Surgical Technologies, Inc. with facilities located in Irvine and Portola Valley, CA (USA), is a privately held cardiovascular medical device company focused on the heart valve replacement market. Founded in 2002 by Dr. Thomas J. Fogarty and noted heart valve designer, Ernie Lane, Arbor is developing multiple technologies that have the potential to deliver significant clinical benefit to patients worldwide. Arbor intends to develop and commercialize its core technologies in varying combinations, giving the company the opportunity to create a broad portfolio of product offerings. Currently in clinical trials, Arbor is developing a tissue heart valve family of products designed for improved performance over existing valves and compatible implantation tools that simplify and speed valve replacement surgery. Arbor Surgical Technologies mission is to simplify cardiac valve surgery through the innovative development of a less invasive, unique implantation system and valves with superior performance and durability. Partnering with physicians, we will improve patient recovery by less invasive techniques and reduced surgery time. Ethical behavior with employees, surgeons, patients and suppliers is the keystone to our success.
Ouroboros Medical is a medical devices for minimally invasive spinal fusion
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.